Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer.

This study analyzed tumor-specific MHC-II (tsMHC-II) expression as a predictive biomarker in the phase III NeoTRIP trial...

Continue ReadingTumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer.

Germline Testing: The Therapeutic Biomarker You Can’t Afford to Miss

You may already be ordering germline testing at rates well above the national average — but across the U.S., most eligible patients still aren’t tested: Ovarian cancer: ~39% receive germline…

Continue ReadingGermline Testing: The Therapeutic Biomarker You Can’t Afford to Miss

Tumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02).

This multicenter phase II trial evaluated trastuzumab emtansine (T-DM1) in 36 patients with HER2-positive metastatic bre...

Continue ReadingTumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02).